About Jeffrey Landau
Jeffrey Landau is a chief executive officer and director at Stipple Bio.
Jeffrey Landau reports to the SEC as an officer of 1 public company: CytomX Therapeutics (CTMX).
Jeffrey Landau first appears on SEC filings in 2022.
Experience
This experience comes from Jeffrey Landau's profile and from SEC filings. For roles taken from filings, the years are when the filings name Jeffrey Landau in the role, so the role may have started earlier or lasted longer.
Stipple Bio, Inc. Current
Executive officer
Chief Executive Officer, Board Member (2025 – Present)
2025 – Present · Cambridge, MA
Develops targeted cancer medicines for people with cancer.
CC
California Life Sciences (CLS) Current
Board Member
2023 – Present
SB
Sunterra Bio Current
Co-founder, Board Member
2019 – Present
BA
Band of Angels Current
Healthcare VC
2014 – Present
CI
CytomX Therapeutics, Inc.
Chief Business Officer and Head of Strategy
2021 – 2025 · Public company (CTMX)
CB
Catalyst Biosciences
SVP Corporate Developmnet and Strategy
2017 – 2021
TP
Threshold Pharmaceuticals
Corporate Development and Product Strategy
2012 – 2016
Key Colleagues at Startups
The people Jeffrey Landau works with at each company, as listed on that company's latest Form D.
Stipple Bio, Inc. · Form D, Apr 6, 2026
Vineeta Agarwala
Director
GV
Greg Verdine
Independent Director
TS
Thilo Schroeder
Managing Partner, Nextech and director
OH
Owen Hughes
Independent Director
AR
Aaron Ring
Associate Professor, Fred Hutch and director
DD
Derek DiRocco
Partner, RA Capital Management and director